Apellis Pharmaceuticals Inc (NASDAQ:APLS) price on Thursday, July 03, rose 2.47% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $18.26.
A look at the stock’s price movement, the close in the last trading session was $17.82, moving within a range at $17.73 and $18.26. The beta value (5-Year monthly) was 0.669. Turning to its 52-week performance, $42.47 and $16.10 were the 52-week high and 52-week low respectively. Overall, APLS moved -2.98% over the past month.
Apellis Pharmaceuticals Inc’s market cap currently stands at around $2.29 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-07.
Analysts have a consensus estimate of 186.4M for the company’s revenue for the quarter, with a low and high estimate of 170.36M and 201.84M respectively. The average forecast suggests down to a -6.65% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 769.07M, representing a -1.57% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that APLS is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
14 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 11 recommend APLS as a Buy and 1 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
APLS’s current price about -0.74% and 0.65% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.59, while 7-day volatility ratio is 4.49% and 4.03% in the 30-day chart. Further, Apellis Pharmaceuticals Inc (APLS) has a beta value of 0.75. Analysts have given the company’s stock an average 52-week price target of $76, forecast between a low of $39 and high of $113. Looking at the price targets, the low is -113.58% off current price level while to achieve the yearly target high, price needs to move -518.84%. Nonetheless, investors will most likely welcome a -316.21% jump to $76 which is the analysts’ median price.
If we refocus on Apellis Pharmaceuticals Inc (NASDAQ:APLS), historical trading data shows that trading volumes averaged 2.01 over the past 10 days and 2.56 million over the past 3 months. The company’s latest data on shares outstanding shows there are 125.66 million shares.
The 17.70% of Apellis Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 100.06% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 25.14 million on 2025-06-13, giving us a short ratio of 10.34. The data shows that as of 2025-06-13 short interest in Apellis Pharmaceuticals Inc (APLS) stood at 2638.9998 of shares outstanding, with shares short falling to 27.25 million registered in 2025-05-15. Current price change has pushed the stock -49.68% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the APLS stock continues to rise going into the next quarter.
